Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

The schedule is longer, the table much bigger, and there are even Thursday games on the docket. [ MORE: UEFA Champions League hub — Format, schedule, more] Below you’ll find the table, 1-36, as well ...

1 Day ROG -1.02% DJIA 0.59% S&P 500 0.38% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Want to take your Luck to the next level for a Luck weekend? Get a Pets Go cocktail. The Pets Go Cocktail mystery is one of the biggest out there at launch. Here’s what we know about it. Sipping on a ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.